CD40LG and breast carcinoma: Furthermore, Bishop et al. confirmed the active role of CD40L in osteoclast formation and inventively applied TRAF-STOP to diseases associated with osteoclasts in vivo, revealing that TRAF-STOP could inhibit bone resorption caused by breast cancer (Bishop et al., 2020).